Dr. Jay Yang, MD

Dr. Yang practices at Karmanos Cancer Center in Detroit, Michigan, part of McLaren Health Care.

Dr. Yang's NPI, 1316069768, was assigned on April 5, 2007. Dr. Yang graduated from University of Michigan Medical School in 1998. Dr. Yang holds Michigan license 4301084642.

Dr. Yang's primary practice is Karmanos Cancer Center, at 4100 John R, Detroit, MI 48201 in Wayne County. The practice phone is (800) 576-6266.

Dr. Yang's primary practice is Karmanos Cancer Center in Detroit, Michigan, part of McLaren Health Care. Dr. Yang is also affiliated with DMC Harper University Hospital. The medical group on file is Wayne Health. Dmand AI also links Dr. Yang to 1 more hospital, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Yang practices, 3 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Yang's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Yang is licensed in Michigan.

CMS data shows 514 Medicare services from Dr. Yang across 6 procedure codes in 2024, for 186 Medicare patients. Medicare paid $34,775 for them.

CMS counts 186 Medicare patients who saw Dr. Yang in 2024. The largest group is 65 to 74, with 95 patients. 71% of them have high blood pressure, and 65% have high cholesterol. 22% are also on Medicaid. Their average risk score is 2.50, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Yang's median patient age at 67, with 58% women.

In 2024, Dr. Yang wrote 419 Medicare Part D claims for 80 patients. 48% of them were for generic drugs. CMS names the drug for 288 of them, across 14 drugs with 11 or more claims each, at $3,046,638 in total drug cost. In 2023, CMS named 411 claims across 15 drugs.

Dr. Yang accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Yang as offering telehealth.

Dmand AI links 34 papers to Dr. Yang, published from 2012 to 2025. 2021 was the busiest year, with 5. The most frequent topics are Leukemia, Myeloid, Acute, Antineoplastic Agents and Bridged Bicyclo Compounds, Heterocyclic. Dr. Yang has published most often in Expert Rev Hematol. Dr. Yang's most frequent co-authors are Jeffrey W. Taub, MD, Kathryn Maryse White, MD and Anjali S. Advani, MD.

Dmand AI links Dr. Yang to 13 clinical trials, 5 of them phase 2 studies. 8 are still active or recruiting. Conditions studied include Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute and Leukemia, B-Cell. National Cancer Institute (NCI) sponsors the most, 5. Open Payments lists research payments to Dr. Yang that name 3 trials.

CMS Open Payments shows 26 general payments to Dr. Yang from 12 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 41% of the total. Agios Pharmaceuticals, Inc. paid the most, $3,833. It also lists 5 research payments totaling $2,856 from 2016 to 2024, naming 3 clinical trials.

Dr. Yang graduated from University of Michigan Medical School in 1998.